key: cord-0050763-zpd08bdv authors: nan title: Full programme date: 2020-09-28 journal: Neuromuscul Disord DOI: 10.1016/s0960-8966(20)30614-3 sha: 38602ab3b5920b79d2d29f36b36118e4e710890c doc_id: 50763 cord_uid: zpd08bdv nan P.118 Elevation of fast, but not slow TnI in plasma from Duchenne and Becker muscular dystrophy patients suggests differential fiber response to disease This is one of the most popular sessions of the annual WMS Congress. The session moderators, with support from the programme committee, select 6 posters for short oral presentations that they feel are of particular interest to the neuromuscular community. The poster may address controversial or polarising topics or topics that aren't regularly covered in plenary lectures, but are nevertheless scientifically sound and relevant. Escalating dose and randomized, controlled study of high-dose nusinersen in SMA; study design and updated enrollment for the DEVOTE Study R. Finkel Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study R. Finkel Minimally invasive fusionless surgery offers satisfactory early and definitive treatment for scoliosis in SMA children: Our experience over a decade M Nusinersen effect in infants who initiate treatment in a presymptomatic stage of SMA: NURTURE results Impact of Continued Nusinersin treatment on Caregiver Experience and Health-Related Quality of Life in Later-onset SMA: Results From the Myostatin dynamics in health and disease: Pharmacologic effects of SRK-015, a highly selective monoclonal antibody inhibitor of myostatin activation K. Long 12-month pooled safety and efficacy outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) Jewelfish: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy receiving treatment with risdiplam (RG7916) 274 RAINBOWFISH: A study of risdiplam (RG7916) in infants with presymptomatic spinal muscular atrophy (SMA) Monitoring Chilean SMA patients treated with nusinersen. A single-center experience C. Castiglioni Distinct disease-activity markers between inflammatory and dystrophic myopathies revealed by the multi-exponential behaviour of water T2-relaxation E. Caldas de Almeida Araujo TSP-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis X Optimizing hand-function patient outcome measures for inclusion body myositis A. Lin; C. Siener; A. Faino Autoantibodies targeting membrane repair proteins represent a novel pathologic mechanism in idiopathic inflammatory myopathy K. McElhanon; N. Young Mitochondrial DNA rearrangements and point mutations in inclusion body myositis A. Oldfors; C. Hedberg-Oldfors Clinical onset of sporadic inclusion body myositis after years of immunosuppressive therapy M. Winkler; C. von Landenberg; C. Kornblum; J. Reimann P.306 Clinical correlates of KLRG1+ T cells in inclusion body myositis N 308 Characteristics of chest CT-scan patterns of idiopathic inflammatory myopathies: association with myositis-specific autoantibodies K. Mariampillai; A. Laporte; Y. Allenbach; O. Benveniste Immune mediated necrotising myopathy: a treatable condition missed in the Arab and African regions R Myopathy in scleroderma/systemic sclerosis patients: From a histopathological point of view Y. Chen Amyopathic" MDA5-positive dermatomyositis with severe lung involvement presents with myositic morphological features B. Englert; W. Stenzel Mitochondrial diseases & Metabolic myopathies Design of a phase 3 prospective clinical study for the treatment of thymidine kinase 2 deficiency Mitochondrial DNA mutant load in A3243G mutation and clinical correlation H. Lee; Y. Lee P Collaborative model for diagnosis and treatment of very rare diseases: experience in Spain with thymidine kinase 2 deficiency C. Paradas 316 MT1621 for thymidine kinase 2 deficiency (TK2d): mechanism of action is via mitochondrial DNA incorporation L. Tsuruda; D. Kenny 317 A novel m.9143T>C variant --intercurrent severe lactate acidosis and immunodeficiency as an extension of the phenotypic spectrum in MT-ATP6 mutations D 318 RBCK1-related disease: A rare multisystem disorder with polyglucosan storage, autoinflammation, recurrent infections, skeletal, and cardiac myopathy R. Phadke Analysis of morbidity and mortality in untreated patients with thymidine kinase 2 deficiency C. Domínguez-González Mitochondrial myopathy in X-linked creatine transporter deficiency due to a novel mutation of SLC6A8 gene M. Bisciglia; A. Busson 323 A genetic basis is identified in 74% cases of paediatric hyperCKaemia without weakness W. Wong; S. Bryen; A. Bournazos; S. Bommireddipall Characterization of mitochondrial respiratory chain complexes in reversible infantile respiratory chain deficiency S. Roos; C. Hedberg-Oldfors A. Oldfors New genes and diseases / NGS & related techniques Whole exome sequencing identifies two novel candidate genes and extends the diagnostic spectrum of patients with neuromuscular diseases R. Rossi Whole exome and whole genome sequencing for the genetic diagnosis of dystrophinopathies R. Selvatici Neuromuscular disease variant of unknown significance (VUS) resolution using muscle biopsy evaluation: The Iowa experience K Whole exome sequencing in the pediatric neuromuscular clinic An approach to prioritizing novel disease gene candidates and investigating their role in muscle biology and disease Role of whole exome sequencing in identifying rare genetic variants in a cohort of patients presenting with congenital myopathy A. Aykanat; C. Genetti; W. Win Progressive proximal muscle weakness, myopathic muscle biopsy and a novel candidate gene S Introme identifies non-canonical splice-altering variants in neuromuscular patients resulting in multiple new genetic diagnoses P. Sullivan; C. Mayoh Registries, Care, Quality of Life, management of NMD 335 Cardiac involvement in Duchenne and Becker muscular dystrophy G Novel and more sensitive criteria for identifying chronic respiratory failure in progressive neuromuscular disease O Variability of cardiac function in patients with Duchenne muscular dystrophy experiencing sudden onset chest pain and electrocardiographic changes A. Yamamoto Hospital goes to School": A psychoeducational program to raise awareness about neuromuscular disorders in schools to prevent social exclusion I. Zschaeck; A. Colomer; D Coalition to cure calpain 3: A patient organization committed to treating and ultimately curing limb girdle muscular dystrophy type 2A Use of the assessment of caregiver experience with neuromuscular disease (ACEND with SMA) -a caregiver experience from a single center Life expectancy and causes of death in patients with Duchenne muscular dystrophy L. Wahlgren; A. Kroksmark The rare disease cures accelerator-Data and analytics platform: Value for drug development in muscle diseases J. Larkindale Rasch analysis of the pediatric quality of life inventory 4.0 generic core scales administered to patients with Duchenne muscular dystrophy E. Landfeldt Child-to-adult healthcare transition for inherited muscle diseases: a single-center study in suburbs of Tokyo 347 Illness identity in young adults with neuromuscular disorders S. Geuens 348 NMD4C: A new neuromuscular disease network for Canada K. Amburgey; J. Dowling Subspecialty healthcare utilization in pediatric patients with muscular dystrophy in the United States S. Matesanz Lin 19:30-20:30 From the spinal cord to the muscle Molecular and clinical assessments of spinal cord disease, sarcoglycanopathy, and dysferlinopathy are discussed, along with genetic therapy for the latter. Session Moderator: John Vissing Assistant Moderator: Mo Zhao O.09 Spinal cord MRI for early detection of presymptomatic pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study G. Querin European collaboration on the clinical and genetic spectrum of sarcoglycan-deficient muscular dystrophy Limb girdle muscular dystrophy R2 and Miyoshi myopathy are not distinct clinical phenotypes in dysferlinopathy U Midi-Dysferlin gene therapy for dysferlinopathies O. Ballouhey; S. Courrier 00 Comfort break, poster viewing, sponsors & exhibiton, and chat room 21:00-22:00 Highlights across Myology From basic science to clinical research, investigators use a variety of approaches to assess NM disease, including calcium studies, gene editing, large-scale electron microscopy, and pre-conception carrier screening Altered calcium handling in a zebrafish model of SELENON congenital muscular dystrophy M Gene editing using CRISPR/CAS9 in an animal model of nemaline myopathy N. Sabha Large-scale electron microscopy reveals capillary pathology in muscle samples of patients with systemic sclerosis C. Dittmayer; E. Siegert; A. Uruha Results of a preconception carrier screening trial including severe neuromuscular disorders S Laing LBO 2 A novel form of muscular dystrophy associated with mutations in JAG2 Peter Kang LBO 3 Expression of apparent full-length dystrophin in skeletal muscle in a first